Unknown

Dataset Information

0

Impact of disease-modifying treatments on humoral response after COVID-19 vaccination: A mirror of the response after SARS-CoV-2 infection.


ABSTRACT:

Objective

To analyze the humoral response after COVID-19 vaccination in patients with multiple sclerosis (MS) according to disease-modifying treatments (DMTs) and in comparison with the humoral response after SARS-CoV-2 infection.

Methods

We included 28 MS patients with serological results after COVID-19 vaccination (Pfizer-BioNTech or Moderna ARNm) and 61 MS patients with serological results after COVID-19 (COVID-19 group) among patients followed up at the MS Center of Strasbourg, France, between January and April 2021. The primary endpoint was the IgG index according to DMTs (anti-CD20 mAb, sphingosine 1-phosphate receptor [S1PR] modulator and other treatments) and COVID-19 vaccine or COVID-19 groups.

Results

In the vaccinated MS patients, the median IgG index was lower in patients treated with anti-CD20 mAb and in patients treated with S1PR modulator compared to patients receiving other or no DMTs (4.80 [1.58-28.6], 16.5 [16.3-48.5], 1116 [434-1747] and 1272 [658-1886], respectively, P<0.001). Similar results were found for MS patients after COVID-19.

Conclusions

Patients with MS and treated with S1PR modulators or anti-CD20 mAb had a reduced humoral response after COVID-19 vaccine.

SUBMITTER: Bigaut K 

PROVIDER: S-EPMC8206590 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Impact of disease-modifying treatments on humoral response after COVID-19 vaccination: A mirror of the response after SARS-CoV-2 infection.

Bigaut K K   Kremer L L   Fleury M M   Lanotte L L   Collongues N N   de Seze J J  

Revue neurologique 20210616 10


<h4>Objective</h4>To analyze the humoral response after COVID-19 vaccination in patients with multiple sclerosis (MS) according to disease-modifying treatments (DMTs) and in comparison with the humoral response after SARS-CoV-2 infection.<h4>Methods</h4>We included 28 MS patients with serological results after COVID-19 vaccination (Pfizer-BioNTech or Moderna ARNm) and 61 MS patients with serological results after COVID-19 (COVID-19 group) among patients followed up at the MS Center of Strasbourg  ...[more]

Similar Datasets

| S-EPMC8461365 | biostudies-literature
| S-EPMC9686308 | biostudies-literature
| S-EPMC9111759 | biostudies-literature
| S-EPMC8776512 | biostudies-literature
| S-EPMC9979636 | biostudies-literature
| S-EPMC9478933 | biostudies-literature
| S-EPMC9123863 | biostudies-literature
| S-EPMC10224652 | biostudies-literature
| S-EPMC9659602 | biostudies-literature